Rocket Pharmaceuticals
The Empire State Building
350 Fifth Ave, Suite 7530
New York
New York
10118
United States
Tel: 646-440-9100
Fax: 646-224-9585
Website: https://www.rocketpharma.com/
Email: info@rocketpharma.com
175 articles about Rocket Pharmaceuticals
-
Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
11/3/2022
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today reports financial results for the quarter ending September 30, 2022, and updates from the Company’s key pipeline developments, business operations and upcoming milestones.
-
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
10/12/2022
Rocket Pharmaceuticals, Inc. announces data presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy in Edinburgh, United Kingdom, taking place October 11-14, 2022.
-
Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting on the Mesa
10/10/2022
Rocket Pharmaceuticals, Inc. today announced that Raj Prabhakar, M.B.A., Chief Business Officer, will deliver an in-person company presentation at the 2022 Cell & Gene Meeting on the Mesa on Tuesday, October 11, at 2:30 p.m. PT in Carlsbad, CA.
-
Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock - October 04, 2022
10/4/2022
Rocket Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 6,800,000 shares of its common stock at a public offering price of $14.75 per share.
-
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock - October 03, 2022
10/3/2022
Rocket Pharmaceuticals, Inc., a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of investigational genetic therapies for rare childhood disorders with high unmet need, announced that it has commenced an underwritten public offering of $100 million of shares of its common stock.
-
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
9/30/2022
Rocket Pharmaceuticals, Inc. announces positive clinical updates from its Phase 1 Danon Disease Trial for RP-A501 through an oral poster session at the Heart Failure Society of America Annual Scientific Meeting 2022.
-
Shares of Rocket Pharmaceuticals jumped Friday morning after the company announced positive clinical updates from a Phase I study of patients diagnosed with Danon disease.
-
Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference
9/27/2022
Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference.
-
Shares of Renovacor, Inc. stock are surging in premarket trading following Rocket Pharmaceuticals' announcement it will acquire the company in an all-stock transaction valued at $53 million.
-
Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy
9/20/2022
Rocket Pharmaceuticals, Inc. and Renovacor, Inc. announced a definitive agreement under which Rocket will acquire Renovacor in an all-stock transaction for an implied value of approximately $2.60 per share, based on the volume weighted average trading price of Rocket shares of $15.51 for the 30 trading days through and including Monday, September 19, 2022.
-
Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
9/16/2022
Rocket Pharmaceuticals, Inc. today announces that the Company will present updated clinical data on its Phase 1 Danon Disease Trial for RP-A501 during an oral poster session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 to be held Sept. 30 – Oct. 3, 2022.
-
Rocket Pharmaceuticals to Present at Morgan Stanley 20th Annual Global Healthcare Conference
9/6/2022
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), today announces that Gaurav Shah, M.D., Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, Sept. 13, at 3:30 p.m. ET.
-
Rocket Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
8/8/2022
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), today reports financial results for the quarter ending June 30, 2022, and updates from the Company’s key pipeline developments, business operations and upcoming milestones.
-
Rocket Pharmaceuticals Appoints Mayo Pujols as Chief Technical Officer and Strengthens Manufacturing Capabilities
7/27/2022
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces the appointment of Mayo Pujols as Chief Technical Officer (CTO) and Executive Vice President.
-
Rocket Pharmaceuticals to Present at William Blair Biotech Focus Conference
7/8/2022
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that Gaurav Shah, M.D., Chief Executive Officer, will participate in a fireside chat at the William Blair Biotech Focus Conference 2022 on July 12-13, 2022, at the St. Regis Hotel in New York.
-
The 25th Annual Meeting of the American Society of Gene and Cell Therapy wrapped up on Thursday. BioSpace looks at some of the highlights.
-
Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
5/19/2022
Rocket Pharmaceuticals, Inc. announces positive top-line safety and efficacy data from its Phase 2 pivotal trial for severe Leukocyte Adhesion Deficiency-I at the 25th Annual Meeting of the American Society of Gene and Cell Therapy.
-
The American Society of Gene & Cell Therapy (ASGCT) Annual Meeting kicked off Monday with multiple presentations highlighting the potential of new treatments for a myriad of diseases.
-
Rocket Pharmaceuticals Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
5/16/2022
Rocket Pharmaceuticals, Inc. announces positive clinical updates from its Phase 2 pivotal trial for Fanconi Anemia and Phase 1 trials for Danon Disease and Pyruvate Kinase Deficiency at the 25th Annual Meeting of the American Society of Gene and Cell Therapy.
-
Rocket Pharmaceuticals to Present at UBS Global Healthcare Conference
5/11/2022
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that Gaurav Shah, M.D., Chief Executive Officer, will deliver a company presentation at the UBS Global Healthcare Conference on Tuesday, May 24 at 7:45 a.m. ET, in New York.